Boston-based Temu, a new online retailer linked to Pinduoduo, has quickly surpassed Amazon and Walmart as the most downloaded app in the United States.
Temu, which shares the same owner as Chinese social commerce giant Pinduoduo, unveiled a commercial during the Super Bowl encouraging consumers to “shop like a billionaire.”
According to the commercial by Ternu, which sells virtually everything from home goods to apparel to electronics, its customers can shop with a sense of freedom because of the price they offer.
The 30-second commercial offers users the opportunity to feel like they are splurging by making numerous inexpensive purchases.
According to Sensor Tower, the Temu application has received 24 million downloads since its launch in September and boasts more than 11 million active users per month.
Abe Yousef, a senior insights analyst at the analytics company Sensor Tower, Temu outperformed Amazon, Walmart, and Target in terms of US app installations in the fourth quarter of last year.
The firm is already plans to expand to Canada.


Columbia Student Mahmoud Khalil Fights Arrest as Deportation Case Moves to New Jersey
Huawei Launches Mate XT2 Foldable Phone in China
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities
Gold Prices Rise as Yen Rally Weakens Dollar
Disaster or digital spectacle? The dangers of using floods to create social media content
The American mass exodus to Canada amid Trump 2.0 has yet to materialize
Canada Retaliatory Tariffs on U.S. Goods Take Effect
South Korea GDP Surges on Chip and AI Boom
TSMC August Revenue Jumps 53% on AI Chip Demand
Google promotes ‘teacher approved’ apps for kids. Here’s what parents should know
Australia Plans New Rules Giving Users Control Over Social Media Feeds
Kioxia Rules Out SK Hynix Manufacturing Partnership
Blackstone Eyes $2 Billion ZO Skin Health Sale
Asian Stocks Fall as Oil Tops $100, Yields Rise
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows
Anthropic Drops $6 Billion Decart AI Acquisition Talks
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 



